세계의 유전자 편집 시장 예측(-2030년)

Market Overview

The Gene editing Market size is projected to register a CAGR of 20.9% during the forecast period. The developing number of key drives and expanding subsidizing for genetic exploration are main considerations driving the market development.

Genomic editing alludes to the procedures and methods used to alter the genetic data of any living life form. Genome editing includes the alteration of genes in numerous areas utilizing recombinant innovation, which increments addition accuracy and diminishes cell poisonousness. An assortment of innovations permits researchers to modify a creature's DNA. These advancements empower adding, erasing, or changing genetic material at explicit areas inside the genome. Ascend in the quantity of key drives as consolidations, acquisitions, item endorsement, coordinated efforts, and organizations to acquire an upper hand and proposition progressed treatment choices for genomic editing.

Market Segmentation

Technology-based segments of the gene editing market include CRISPR, TALEN, ZFN, antisense, and others.

Genetic engineering, gene therapy, cell line engineering, and other applications make up the market segments of gene editing.

Gene editing market segmentation is based on biotechnology and pharmaceutical firms, contract research organizations (CROs), university & government research institutes, and contract research organizations (CROs).

Regional Insights

The North American gene editing market is supposed to represent over USD 2 billion in 2022 and is supposed to show a 21.19% CAGR during the review time frame. This is credited to the expansion of malignant growth and other genetic problems, a developing inclination for customized medication, an expansion in private and public area financing, and quick progressions in sequencing and gene editing innovations are driving the market for gene editing in the North America region.

Europe gene editing market is supposed to represent the second-biggest market share because of mechanical headways in medical services IT like the utilization of Computerized reasoning (man-made intelligence) to fabricate CRISPR frameworks are driving development drive the market development of gene editing in Europe.

The Asia-Pacific gene editing market is supposed to develop at a CAGR of 24.03% from 2023 to 2030. This is because of the rising mechanical leap forwards, a flourishing biotechnology industry in arising regions, and the rising commonness of disease and other genetic irregularities.

The Rest of the World incorporates the Middle East, Africa, and Latin America. Middle East holds the significant market share in the Middle East and Africa region because of a few main considerations, for example, developing government support, rising public-private organizations, and expanded subsidizing are adding to the region's biotechnology industry's development.

Major Players

Key Companies in the Gene editing Market Include GE Healthcare (US), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Lonza (Switzerland), GenScript (US), Horizon Discovery Ltd (UK), OriGene Technologies, Inc (US), Integrated DNA Technologies, Inc (US), New England Biolabs, Inc (US), and Sangamo Therapeutics (US).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING FUNDING FOR GENETIC RESEARCH
  • 4.2.2 RISING INCIDENCE OF GENETIC DISORDERS
  • 4.2.3 GROWING NUMBER OF STRATEGIC INITIATIVES
• 4.3 RESTRAINTS
  • 4.3.1 OFF-TARGET EFFECTS OF CRISPR TECHNOLOGY
  • 4.3.2 HIGH COST OF EQUIPMENT
• 4.4 OPPORTUNITIES
  • 4.4.1 INCREASING APPLICATION AREAS OF GENE EDITING

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL GENE EDITING MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON REGIONS
  • 5.3.3 IMPACT ON SUPPLY GAP ANALYSIS
  • 5.3.4 IMPACT ON PRICING

6 GLOBAL GENE EDITING MARKET, BY TECHNOLOGY

• 6.1 OVERVIEW
• 6.2 CRISPR
• 6.3 TALEN
• 6.4 ZFN
• 6.5 ANTISENSE
• 6.6 OTHERS

7 GLOBAL GENE EDITING MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 GENETIC ENGINEERING
• 7.3 GENE THERAPY
• 7.4 CELL LINE ENGINEERING
• 7.5 OTHERS

8 GLOBAL GENE EDITING MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
• 8.3 CONTRACT RESEARCH ORGANIZATIONS
• 8.4 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES

9 GLOBAL GENE EDITING MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL GENE EDITING MARKET
• 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL GENE EDITING MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT EXPANSION AND LAUNCH
  • 10.6.2 AGREEMENT/COLLABORATION
• 10.7 FINANCIAL MATRIX
  • 10.7.1 SALES (USD MILLION), 2021
  • 10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

11 COMPANY PROFILES

• 11.1 BIO-RAD LABORATORIES, INC
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 GE HEALTHCARE
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 GENSCRIPT
  • 11.3.1 COMPANY OVERVIEWS
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 INTEGRATED DNA TECHNOLOGIES, INC
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 NEW ENGLAND BIOLABS
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 SANGAMO THERAPEUTICS
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 THERMO FISHER SCIENTIFIC, INC
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 LONZA
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 HORIZON DISCOVERY LTD
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 ORIGENE TECHNOLOGIES, INC
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS